Johnson & Johnson Halts Nipocalimab Trial for Rheumatoid Arthritis After Failure
ByAinvest
Friday, Aug 29, 2025 7:13 am ET1min read
ABBV--
The trial, which involved patients with rheumatoid arthritis, did not demonstrate that the combination therapy provided additional benefits over anti-TNFα therapy alone. Despite the lack of new safety issues, Johnson & Johnson concluded that the drug combination did not warrant further clinical development for this indication [2].
While this setback impacts Johnson & Johnson's plans for nipocalimab in rheumatoid arthritis, the company continues to project over $5 billion in non-risk-adjusted peak-year operational sales for the drug across other conditions, including various rheumatic diseases [1].
The development of nipocalimab had been seen as a potential rival to AbbVie's (ABBV) blockbuster drug Humira, which has faced competition from U.S. biosimilars in recent years. Humira's sales potential, previously worth nearly $21 billion in 2021, has been under threat from these competitors [1].
This decision underscores the challenges pharmaceutical companies face in developing new therapies and highlights the importance of rigorous clinical trials in assessing their efficacy.
References:
[1] https://seekingalpha.com/news/4490373-jj-halts-rd-potential-rival-abbvies-humira
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/jj-drops-development-combination-arthritis-drug-after-trial-setback-2025-08-28/
JNJ--
Johnson & Johnson has halted studies for a potential rival to AbbVie's Humira after a mid-stage trial setback. The trial evaluated Johnson & Johnson's experimental antibody therapy, nipocalimab, for rheumatoid arthritis. The company decided to discontinue the therapy due to the failure of the trial.
Johnson & Johnson (JNJ) has decided to discontinue the development of its experimental antibody therapy, nipocalimab, for rheumatoid arthritis after a mid-stage trial failed to show significant added benefits over existing anti-tumor necrosis factor alpha (anti-TNFα) therapies. The decision follows the results of the Phase 2a DAISY proof-of-concept study, which evaluated nipocalimab in combination with anti-TNFα therapies [1].The trial, which involved patients with rheumatoid arthritis, did not demonstrate that the combination therapy provided additional benefits over anti-TNFα therapy alone. Despite the lack of new safety issues, Johnson & Johnson concluded that the drug combination did not warrant further clinical development for this indication [2].
While this setback impacts Johnson & Johnson's plans for nipocalimab in rheumatoid arthritis, the company continues to project over $5 billion in non-risk-adjusted peak-year operational sales for the drug across other conditions, including various rheumatic diseases [1].
The development of nipocalimab had been seen as a potential rival to AbbVie's (ABBV) blockbuster drug Humira, which has faced competition from U.S. biosimilars in recent years. Humira's sales potential, previously worth nearly $21 billion in 2021, has been under threat from these competitors [1].
This decision underscores the challenges pharmaceutical companies face in developing new therapies and highlights the importance of rigorous clinical trials in assessing their efficacy.
References:
[1] https://seekingalpha.com/news/4490373-jj-halts-rd-potential-rival-abbvies-humira
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/jj-drops-development-combination-arthritis-drug-after-trial-setback-2025-08-28/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet